The Desmoid Tumor Research Foundation

March 2022

Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients

Author Information

Papadopoulos S (1), Koulouris P (1), Royer-Chardon C (2), Tsoumakidou G (3, 4), Dolcan A (1), Cherix (4, 5), Matter M (4, 6), Omoumi P (3,4), Digklia A (1, 4).

(1) Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. (2) Department of Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. (3) Department of Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. (4) Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland. (5) Department of Orthopaedics and Traumatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. (6) Department of Visceral Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.artment of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Publication

Front Endocrinol (Lausanne)

Summary

Tyrosine kinase inhibitors (TKIs) are nowadays a valuable treatment of desmoid tumors, a rare mesenchymal neoplasm. Although many side effects of imatinib and pazopanib, commonly or rarely occurring, have been described, reactional lymphadenopathy has not yet been reported. In this publication, we report two cases of patients with desmoid tumors, treated with pazopanib and imatinib, who developed reactional lymphadenopathy. As this side effect is presented as a newly formed mass, it can result in new diagnostic questions and added imaging tests and can even lead to discontinuation of the treatment. This report may help the clinicians facing similar problems adopt a "watch and wait" approach.

View Abstract